Cholangiocarcinoma (CCA) is one of the most aggressive tumors of the hepatobiliary system and is often only diagnosed at an advanced stage. Advances in molecular diagnostics and targeted therapy are increasingly opening up personalized treatment options.
Autoren
- Dr. oec. Odile Schwarz-Herion
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
- approved FGFR inhibitors pemigatinib and futibatinib
- BRAF-V600E
- Cholangiocarcinoma
- Clinical studies Cholangiocarcinoma
- Combination of dabrafenib and trametinib
- Dabrafenib Trametinib
- dMMR
- Entrectinib
- extrahepatic cholangiocarcinoma
- FGFR inhibitors
- FGFR2 fusion
- FIGHT-202 study
- FOENIX-CCA2 study
- Futibatinib
- HER2 amplification
- HER2-positive extrahepatic CCA
- HER2-targeted therapy
- IDH1 mutation
- intrahepatic cholangiocarcinoma
- Ivosidenib effective second-line therapy
- Larotrectinib
- molecular alterations
- molecular diagnostics
- MSI-H
- Next-generation sequencing
- NGS profiling
- NTRK merger
- NTRK mergers
- Pembrolizumab
- Pemigatinib in previously treated patients with FGFR2 fusions
- Personalized oncology
- Prognosis and therapy
- Targeted therapy
- Trastuzumab-based combinations
- TRK Inhibitors
- Tumor Board Switzerland
- tumor-agnostic therapies such as larotrectinib or entrectinib
- Tumors with BRAF V600E mutations
You May Also Like
- Switzerland's First PTH Replacement Therapy
Palopegteriparatide for Chronic Hypoparathyroidism
- Case study
Orofacial Manifestations of Phelan-McDermid Syndrome
- Atherosclerotic Coronary Plaques in High-Risk Patients
Who benefits from preventive PCI?
- Colorectal Cancer
Insulin Resistance, Obesity, and Progression
- Modern asthma therapies
New data on biologics and triple therapy
- From symptom to diagnosis
Abdominal Pain – Focal Nodular Hyperplasia
- Clinically Suspected Arthralgias
“Watchful waiting” or intervention?
- Hepatology and Metabolism